Live tape
Top 8, mentions 7d11,476SPCX2,435 mentions▲ +0.08GOOGL1,989 mentions▲ +0.02META1,794 mentions▲ +0.04TSLA1,707 mentions▲ +0.05NFLX973 mentions▲ +0.03QQQ888 mentions▲ +0.04AMZN848 mentions▲ +0.06NVDA842 mentions▲ +0.06

Equity · Healthcare

AKBA

NASDAQ

Akebia Therapeutics (AKBA)

$0.5707 +0.88% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 23, 2026
Price · Chart
63 sessions
$1.50 $0.50 28 Jul 23 Oct

The line runs $1.28 on 28 July through $0.5707 on 23 October, on a scale from $0.50 to $1.50. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 28 Jul – 23 Oct 2026
Market cap $158.1M
Avg volume 137.3K

as of Oct 23, 2026

Akebia Therapeutics (AKBA) insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 6 Aug 2026

In the 90 days to 26 Oct 2026, no Akebia Therapeutics insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).

Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
06 Aug 2026 Butler John P. CEO and President Option exercise 350,000 $221K

Akebia Therapeutics (AKBA) reported financials

SEC EDGAR XBRL SEC EDGAR

Akebia Therapeutics reported revenue of $236.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$5.3M.

Figure Reported Period
Revenue $236.2M 31 Dec 2025 fiscal year
Net income −$5.3M 31 Dec 2025 fiscal year
Diluted EPS −$0.02 31 Dec 2025 fiscal year
Total assets $349.7M 30 Jun 2026 at period end
Total equity $25.0M 30 Jun 2026 at period end

Akebia Therapeutics (AKBA) earnings

SEC EDGAR

Akebia Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.03; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.03 —
31 Mar 2026 Q1 2026 −$0.03 —
31 Dec 2025 FY 2025 −$0.02 —
30 Sep 2025 Q3 2025 $0.00 —
30 Jun 2025 Q2 2025 $0.00 —
31 Mar 2025 Q1 2025 $0.03 —
31 Dec 2024 FY 2024 −$0.33 —
30 Sep 2024 Q3 2024 −$0.10 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Akebia Therapeutics (AKBA) institutional holders (13F)

SEC Form 13F SEC EDGAR

7 of the 45 institutional funds we track reported a Akebia Therapeutics position for the quarter ended 30 Jun 2026 — a combined $20.5M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Added +410.5% shares 9,151,524 $10.4M
Millennium Management Added +34.0% shares 3,196,605 $3.6M
Two Sigma Investments Added +87.8% shares 2,436,673 $2.8M
Citadel Advisors Held (±25%) +23.6% shares 1,717,659 $2.0M
Renaissance Technologies Trimmed −33.2% shares 1,223,963 $1.4M
Man Group Trimmed −39.7% shares 155,396 $177K
D. E. Shaw & Co. Added +444.7% shares 87,722 $100K

Akebia Therapeutics (AKBA) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 1,314 shares of Akebia Therapeutics failed to deliver (about $1K) — the latest of at least 14 consecutive trading days with recorded fails. The run reaches the start of the window we read, so it may have begun earlier.

Settlement date Shares failed Notional % of shares out
30 Sep 2026 1,314 $1K <0.001%
29 Sep 2026 1,314 $1K <0.001%
28 Sep 2026 1,314 $1K <0.001%
25 Sep 2026 1,314 $1K <0.001%
24 Sep 2026 1,314 $1K <0.001%
23 Sep 2026 1,949 $2K 0.001%
22 Sep 2026 1,314 $1K <0.001%
21 Sep 2026 1,314 $1K <0.001%
18 Sep 2026 151,739 $137K 0.055%
17 Sep 2026 1,314 $1K <0.001%
16 Sep 2026 1,314 $1K <0.001%
15 Sep 2026 1,314 $1K <0.001%
14 Sep 2026 1,314 $1K <0.001%
11 Sep 2026 12,183 $12K 0.004%

Akebia Therapeutics (AKBA): frequently asked questions

From live data

Have Akebia Therapeutics insiders bought or sold shares recently?

In the 90 days to 26 Oct 2026, no Akebia Therapeutics insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).

How many institutions hold Akebia Therapeutics?

7 of the 45 institutional funds we track reported a Akebia Therapeutics position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Akebia Therapeutics had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Akebia Therapeutics is dated 30 Sep 2026, when 1,314 shares failed to deliver.

When did Akebia Therapeutics last report earnings?

Akebia Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$0.03; no next date is announced in SEC filings yet.

What exchange is Akebia Therapeutics listed on?

Akebia Therapeutics trades on NASDAQ under the ticker AKBA.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings